Oncodesign Precision Medicine (XPAR:ALOPM) ROCE % : -87.68% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Oncodesign Precision Medicine ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Oncodesign Precision Medicine's annualized ROCE % for the quarter that ended in Dec. 2023 was -87.68%.

Oncodesign Precision Medicine ROCE % Historical Data

The historical data trend for Oncodesign Precision Medicine's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncodesign Precision Medicine ROCE % Chart

Oncodesign Precision Medicine Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

ROCE %

-59.89

-42.66

-14.89

-72.14

Oncodesign Precision Medicine Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial			-143.90	49.99	-76.11	-87.68	-63.90

Oncodesign Precision Medicine ROCE % Calculation

Oncodesign Precision Medicine's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-9.712	/	( ( (18.37 - 3.964)	+	(16.632 - 4.112) )	/ 2 )
	=	-9.712	/	( (14.406	+	12.52)	/ 2 )
	=	-9.712	/	13.463
	=	-72.14 %

Oncodesign Precision Medicine's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-10.014	/	( ( (14.971 - 4.65)	+	(16.632 - 4.112) )	/ 2 )
	=	-10.014	/	( ( 10.321	+	12.52 )	/ 2 )
	=	-10.014	/	11.4205
	=	-87.68 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Oncodesign Precision Medicine (XPAR:ALOPM) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Oncodesign Precision Medicine ROCE % Related Terms

Thank you for viewing the detailed overview of Oncodesign Precision Medicine's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncodesign Precision Medicine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (XPAR:ALOPM) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ZR8:Germany

Address

18 rue Jean Mazen, Dijon, FRA, 21000

Website

https://www.opm.oncodesign.com

Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.

Oncodesign Precision Medicine Headlines

No Headlines